European Companies Search Engine
EU funding (€4,138,063): Oligonucleotides for Medical Applications Hor21 Aug 2020 EU Research and Innovation programme "Horizon"
Overview
Text
Oligonucleotides for Medical Applications
The use of synthetic oligonucleotides (ONs, short DNA or RNA strands) in the treatment of genetic diseases is a rapidly growing field, and the most promising alternative to gene therapy or small molecules. Most pharmaceutical companies shift from in-house platform development to product-specific licensing and co-development to get ON based therapies past clinical trials. Therefore there is a growing and currently unmet need for a combined academic and industry-based multidisciplinary research to further advance the field by bringing together the separated and fragmented R&D efforts of diverse ON technologies. OLIGOMED will address these needs by: - uniting world-class academic and private sector expertise in ON chemistry, bio-analysis and medical applications - developing a next generation ON platform technology based on combining tailored synthetic ONs with smart delivery - optimising ON therapies through testing in medicinal environments We will use these novel ON technologies to develop innovative treatment options for high-impact genetic diseases, i.e. Huntington’s disease, cardiovascular diseases and cancer. Our European intersectoral and multidisciplinary research and training network for 15 Early Stage Researchers (ESRs) will deliver: -highly skilled scientific staff required to fully exploit ON therapeutics for personalised medicine -top-class training in organic and chemoenzymatic synthesis, ON analysis, and biomedical/medicinal testing -transferable skills courses, specific industry relevant workshops and public engagement activities This combination makes OLIGOMED a truly exciting programme for ESRs. The platform will immediately benefit to both European citizens and commercial partners. In the long term, OLIGOMED`s flexible platform technology will be taken forward by our private sector and research institutions for exploitation and will thus strengthen the European innovation capacity in the field of ON therapies.
Funded Companies:
| Company name | Funding amount |
| Astrazeneca AB | €281,983 |
| Centre National de la Recherche Scientifique CNRS | €274,802 |
| Institute OF Organic Chemistry - Polish Academy OF Sciences | €121,132 |
| Institut National de la Sante et de la Recherche Medicale | €274,802 |
| Karolinska Institutet | €281,983 |
| Krzysztof Kucharczyk Techniki Elektroforetyczne sp. z o.o. | €56,870 |
| Miedzynarodowy Instytut Mechanizmow i Maszyn Molekularnych Polskiej Akademii Nauk | €151,652 |
| Region Stockholm | €281,983 |
| Rise Research Institutes OF Sweden AB | €281,983 |
| Sixfold Bioscience Ltd. | €303,173 |
| The Chancellor Masters and Scholars of the University of Cambridge | €303,173 |
| Universita Degli Studi Di Catania | €56,876 |
| Universita Degli Studi Di Udine | €348,666 |
| Universiteit Gent | €512,640 |
| University of Southampton | €606,345 |
Source: https://cordis.europa.eu/project/id/956070
The filing refers to a past date, and does not necessarily reflect the current state.
